<DOC>
	<DOCNO>NCT00016055</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop cancer cell grow . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining biological therapy chemotherapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness biological therapy combine temozolomide treat patient metastatic melanoma .</brief_summary>
	<brief_title>Biological Therapy Temozolomide Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety interleukin-12-primed activated T cell ( 12ATC ) temozolomide patient metastatic melanoma . - Determine maximum tolerate dose 12ATC patient population . - Determine clinical response patient treat regimen . OUTLINE : This dose-escalation study interleukin-12-primed activate T cell ( 12ATC ) . Patients undergo leukopheresis day 1-3 adequate peripheral blood mononuclear cell ( PBMC ) obtain . The PBMC treat vitro 2 week monoclonal antibody anti-CD3 , interleukin-2 , interleukin-12 form 12ATC . Patients receive oral temozolomide day 15-19 43-47 12ATC IV 15-30 minute day 22 , 25 , 29 , 32 , 36 , 39 , 50 , 53 , 57 , 60 , 64 , 67 absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos 12ATC maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 patient experience dose-limiting toxicity . Patients follow weekly 2 week , every 3 month 1 year , every 6 month 2 year . PROJECTED ACCRUAL : A total 9-18 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic melanoma No ocular mucosal melanoma Must meet one follow criterion : Failed standard salvage therapy Ineligible standard therapy due concurrent illness Declined standard therapy Received least 1 prior therapy metastatic disease Brain metastasis site metastatic disease allow documented evidence progression least 1 prior treatment metastases No leptomeningeal metastasis At least 1 documented site bidimensionally measurable disease MRI CT scan Previously irradiate lesion consider measurable unless documented disease progression radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count great 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL No coagulation disorder thrombophlebitis Hepatic : Bilirubin le 2.0 mg/dL AST ALT less 3 time upper limit normal ( ULN ) Alkaline phosphatase less 3 time ULN Renal : Creatinine le 1.5 time ULN BUN less 1.5 time ULN Cardiovascular : Ejection fraction least 45 % No active ischemia No unstable angina No uncontrolled congestive heart failure Pulmonary : Normal pulmonary function test within past month FEV1 FVC 65 % predict No uncontrolled pulmonary embolism Gastrointestinal : No frequent vomit No medical condition would preclude oral medication intake ( e.g. , partial bowel obstruction ) Other : No prolonged grade 4 myelosuppression prior dacarbazine last 3 week No uncontrolled cortical dysfunction No major medical illness ( e.g. , active systemic infection , autoimmune disease , uncontrolled thyroid abnormality ) No malignancy within past 5 year except resect basal cell carcinoma carcinoma situ cervix No significant psychiatric disease would preclude study compliance No AIDSrelated illness HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics Biologic therapy : More 1 month since prior biologic therapy immunotherapy Chemotherapy : More 1 month since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy : At least 4 week since prior steroid therapy steroidcontaining compound At least 2 week since prior topical inhaled steroid Radiotherapy : See Disease Characteristics More 1 month since prior radiotherapy , interstitial brachytherapy , radiosurgery Surgery : At least 1 week since prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>